What is the recommended dosage of Femoston (estradiol and dydrogesterone) tablets?

Femoston Tablet Dosage Recommendations

The recommended dosage of Femoston (estradiol and dydrogesterone) is 1-2 mg estradiol combined with 5-10 mg dydrogesterone daily, with the specific regimen depending on whether sequential or continuous therapy is desired. 1, 2

Standard Dosage Options

• For sequential combined therapy (inducing withdrawal bleeding):

  • 2 mg estradiol daily for the first 14 days of a 28-day cycle
  • 2 mg estradiol + 10 mg dydrogesterone daily for the remaining 14 days 3

• For continuous combined therapy (avoiding withdrawal bleeding):

  • 1-2 mg estradiol + 5 mg dydrogesterone daily without interruption 2

• For low-dose therapy (minimizing risks):

  • Femoston Low: 0.5 mg estradiol + 2.5 mg dydrogesterone daily in a continuous regimen 4

Administration Guidelines

• Treatment should be initiated with the lowest effective dose to control symptoms 5
• Medication should be taken at the same time each day for optimal effectiveness 1
• Therapy should be reevaluated periodically (every 3-6 months) to determine if continued treatment is necessary 5

Dosage Selection Factors

• Symptom severity: Higher doses (2 mg estradiol) for more severe menopausal symptoms 1
• Bleeding preference: Sequential regimen if withdrawal bleeding is acceptable; continuous regimen if amenorrhea is desired 1
• Risk profile: Lower doses (0.5-1 mg estradiol) for patients with higher cardiovascular or thrombotic risk factors 4

Monitoring and Safety

• Endometrial safety is excellent with both regimens when used as directed:

  • Sequential regimen shows 97.2-99.6% adequate endometrial protection 3, 6
  • Continuous regimen shows 99.6% endometrial protection 2

• Bleeding patterns to expect:

  • Sequential regimen: Cyclic bleeding in approximately 90% of women, typically starting on days 13-14 of the progestin phase 3
  • Continuous regimen: Approximately 80% of women experience no bleeding by the end of one year of treatment 2

Important Considerations

• Femoston should not be used in women with:

  • History of breast cancer or estrogen-sensitive cancers
  • Undiagnosed vaginal bleeding
  • History of deep vein thrombosis or pulmonary embolism
  • Active liver disease 1

• Cardiovascular benefits include:

  • Reduction in total cholesterol (5%) and LDL-cholesterol (20%)
  • Increase in HDL-cholesterol (20%) 7

• Treatment duration should be the shortest possible to achieve therapeutic goals, with periodic attempts to discontinue or taper medication 5